Post by STENTiT

Everyone loves the breakthrough. The science. The technology. The promise of changing patients' lives. But between a promising lab result and a treatment that reaches patients lies a less glamorous reality: manufacturing, quality systems, clinical validation, regulatory pathways. And years of execution. In a recent interview with the Smart BioMaterials Center (SBMC), our CEO Bart Sanders opens up about the journey from academic research and being perceived as an early-career researcher to building a clinical stage company, the challenges of scaling regenerative implants, and why manufacturing is far more than an operational checkbox. For early-stage medtech companies, access to the right ecosystem can make all the difference. That's why our collaboration with SBMC, supported through OPZuid, and its GMP manufacturing facilities plays such an important role in our next chapter. Whether you're building, investing in, or supporting medical innovation, this interview offers an honest perspective on what it takes to move a technology beyond the lab and toward patients. 👇 Interview in comments 🙏 A big thank you to SBMC and OPZuid for supporting innovation and for the opportunity to share our story.